

Original Research

# Cuminaldehyde ameliorates hyperglycemia in diabetic mice

Kannan Duraisamy<sup>1</sup>, Pari Leelavinothan<sup>1,\*</sup>, Paari Ellappan<sup>1</sup>, Tulsi Deepak Singh Balaji<sup>2</sup>, Ponnulakshmi Rajagopal<sup>3</sup>, Selvaraj Jayaraman<sup>4</sup>, Shyamaldevi Babu<sup>4</sup>

<sup>1</sup>Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, 608001 Chidambaram, India

<sup>2</sup>Department of Food and nutrition, Pondicherry University, 605002 Pondicherry, India

<sup>3</sup>Meenakshi Academy of Higher Education and Research, Central Research Laboratory, 600 078 Chennai, India

<sup>4</sup>Department of Biochemistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences Department of Biochemistry, Saveetha University, 600 077 Chennai, India

\*Correspondence: [jayampari@gmail.com](mailto:jayampari@gmail.com) (Pari Leelavinothan)

Academic Editor: Baohong Zhang

Submitted: 31 January 2019 Revised: 27 September 2021 Accepted: 27 September 2021 Published: 21 September 2022

## Abstract

**Background:** Animal-fats are rich in long-chain saturated fatty-acids, well known to induct diabetic distress among ingested insulin-insensitive individuals. In the current-study, bovine-fat was fed to selective mice breeds highly sensitized to heavy dietary lipid load. **Methods:** The later high fat diet (HFD) group indeed undergone diabetic-onset within weeks with a drastically altered feed-behavior pattern. It consumed more food, gained body mass, elevated homeostatic model assessment value and extensively glycosylated Hb trans-porters. **Results:** However, the hypothetical test drug (Cuminaldehyde or CA) with known therapeutic-potential worked-well to balance food efficiency-ratio and Hb- counts closer to control. The fat-soluble phytochemical mono-terpenoid (CA) promoted constitutive mono-hexose (glucose) consuming catabolic-cycles via mono-glycoprotein (insulin) signal-transduction. It resolved diabetogenic-upsurge of gluconeogenic-enzymes, reduced non-sugar (amino/fatty acids) utilization by restricting transamination/dephosphorylation and restored liver-glycogen reserves near to normal-group effectively at 10 mg/kg b.w dose. **Conclusions:** Hence, the nutraceutical-potential (anti-diabetes/transaminitis ability) of administered exogenous redox-active agent CA can be entertained for evoking therapeutic-health in diabetic human-community.

**Keywords:** Cuminaldehyde; High-fat diet; Insulin resistance; Glycosylated hemoglobin; Oral glucose tolerance test

## 1. Introduction

Diabetes mellitus is a chronic metabolic disorder characterized by insufficient insulin secretion, or resistance to insulin action, or both. It is associated with abnormalities in carbohydrate, lipid and protein metabolism, which leads to hyperglycemia, hyperlipidemia, hyperinsulinemia and hypertension [1]. Approximately 425 million people are diabetic worldwide and this number is expected to increase to 629 million by 2045 [2]. Type-2 diabetes is more prevalent than type-1 diabetes, which is primarily associated with food intake and energy expenditure through diet and exercise respectively.

Humans, like other heterotrophic-organisms, are highly dependent on the surrounding nutritional-supplements to conduct biochemical-reactions and cellular-activities as programmed by the physio-anatomical body-system for survival [3]. Unlike photoautotrophic-plants which consumes light to degenerate H<sub>2</sub>O via dehydrogenation/oxidation in thylakoid-membrane, animals generate proton-motive force (PMF) across mitochondrial-membrane through precisely-regulated oxidative-phosphorylation of C<sub>n</sub>(H<sub>2</sub>O)<sub>n</sub> [4]. The ergotrophic-catalysis carried-out by chemically-conserved native constitutive energy-transaction pathway indicating

attained benefit or deficit on fuel-transformation is chiefly streamlined via intermembrane chemiosmotic-threshold [5]. High intensity-photons, as well as high density-protons from the sun-rays/saturated-fats, could potentially impair the electronic-shuttling along with protonic-pumping mechanisms. The fatal redox-imbalance imparted by photo/chemo-respiration is usually repaired with available redox-potentials indigenously present in the chloroplast and mitochondrion respectively. Generally, the producers (autotrophs) contributes novel redox-agents and progressively introduce them into the diet-pool of consumers (heterotrophs) simply due to produce variety and resource availability. Our current study was constructed based upon this theory where the metabolic-stress is stimulated upon a high-caloric animal-based diet which is further suppressed upon the administration of specific plant-based redox-cycling supplements.

Most of the vital nutrients including exogenous redox-regulators are selectively drawn from diet-input through dietary-tract in a low viscous chyme form. Most of the absorbed materials are streamed through blood particles pumped by the cardio-vascular network prior to the assimilation or excretion [6]. Most of the chemical-messengers that govern complex metabolic-processes such as calorie conversion and carbon assimilation inside the



multicellular-mammalian body are preliminarily directed through endocrine-glands. Pancreatic-organ comprises both ducted and ductless dual (exocrine-endocrine) glands capable of secreting duodenal digestive enzymes as well as trans-membranal inductive-hormones with  $\alpha$  and  $\beta$  cells respectively [7]. The physiological functions of the pancreas are therefore very necessary for maintaining basal-nursery, particularly in highly-evolved aerobically-driven hydro-thermal ergonomic-economy. A diet with heavy caloric-density could provoke perturbation in the glandular-responses of the pancreas which simultaneously promote turbulence in the redox-reflexes of respiring-tissues. Recently, many biochemical and pharmaceutical studies refer to type-II diabetes as the persistence of diet-associated metabolic-disturbance due to insulin-resistance and alternatively prefer nutraceutical-assistance [8]. One of the compounds of interest is cuminaldehyde (CA), a fat-soluble semi-oxidized monocyclic-terpenoid derived from *Cuminum cyminum* (cumin). The cumin seeds, called as Cīrakam in the local language, seems to deliver positive therapeutic-potential by counteracting the negative consequence of acquired diabetic-disorder [9]. Hence, the treatise addresses the bioactivity of orally-administered CA during diabetic-onset by evaluating its effective therapeutic-dose for the determination of efficient-treatment protocol.

Two valid reasons for utilizing CA as redox-supplement are attributed to geographic resource-abundance and specific photorespiratory-resistance. India and China are the top-cultivators of cumin seeds, many of the traditional dishes prepared here carry its components as functional and/or aesthetic ingredient [10]. Nevertheless, the role of a strong secondary redox-carrier is mandatory for calming-down the destructive-effects of oxidative-reflux initiated by solar high-intensity electromagnetic-frequencies during the transformation of fruit to seed [11]. Thus, the literature seeks the correlative resemblance of chosen therapeutic-agent in curtailing/cushioning the deteriorative side-effects of ingesting surplus saturated-fats. Additionally, the neutralization/normalization effects of administered-drug on the diet-associated diabetic-distress are communicated in terms of anti-hyperglycemic, anti-insulinemic, and anti-transaminitis principles.

## 2. Materials and methods

### 2.1 Chemicals and reagents

CA was purchased from Sigma Chemical Co. (St. Louis, MO) USA. All other chemicals and solvents used in this study were of the highest analytical grade, procured from HIMEDIA and S. D. Fine Chemicals (Mumbai, India). 4. 1.

### 2.2 Animals

Animals were maintained as per the National Guidelines and Protocols approved by the Institutional Animal Ethics committee (Reg. No. 160/ 1999/CPCSEA, Proposal number: 1166 in 2017). Healthy male C57BL/6J mice (21 days old weighing 18–20 g), obtained from Bio-gen Bangalore were used in this study and maintained in clean polypropylene cages at Rajah Muthiah Medical College and Hospital, Annamalai Nagar, Chennai under standard humidity (65–70%) and temperature ( $23 \pm 2^\circ\text{C}$ ) with constant 12 h light/dark schedule. They were fed with standard mice pellet diet and drinking water was made available *ad libitum*.

### 2.3 Experimental diabetic induction and selection

The normal group was provided with a standard pellet diet, which is commercially obtained from the Institutional Animal Ethics Committee of Rajah Muthiah Medical College and Hospital, Annamalai Nagar and had a fat composition of 4.2%. The HFD experimental group was fed with beef tallow-based high fat diet (carbohydrate 34.5 g, fat 35.8 g, protein 17.7 g, vitamins 1.8 g, minerals 6.8 g and fiber 3.4 g) [12]. Weekly blood samples were collected by pricking the tail using a needle after a 4 h fast and the blood glucose was measured using a glucometer. On the 8th week, animals with a blood glucose of more than 180 mg/dL were considered to be diabetic and were used for the experiment.

### 2.4 Diet and study design

The animals selected for the study were categorized into following hexa-groups with a individual group consisting six animals each. CA was administered through oral gavage.

Group I: Normal or control mice under above-mentioned standard diet, Group II: Mice fed with standard diet for 105 days and then with test-drug Cuminaldehyde for 35 days. Group III: Mice fed with diabetogenic HFD for 105 days. Group IV: diabetic HFD mice with administered CA (2.5 mg/kg body weight) as therapeutic-dose A for the last 35 days. Group V: diabetic HFD mice administered with CA (5 mg/kg b.w) as TD B for the last 35 days. Group VI: HFD diabetic mice administered with CA (10 mg/kg b.w) as TD C by an oral gavage for the last 35 days. At the end of the experimental period, mice were allowed to fast overnight. Then, the mice were sacrificed by cervical dislocation and blood was collected by cutting the jugular vein into heparinized glass tubes. Plasma was isolated from blood samples and stored at 4 to 8 °C. Liver tissue was washed in ice-cold isotonic saline and blotted with a filter paper. A portion of the tissue was weighed, homogenized in 0.1 M Tris-HCl buffer (pH 7.4) and the tissue homogenate was used for carbohydrate metabolic enzyme and hepatic glycogen estimations.

## 2.5 Measurement of plasma parameters

Plasma glucose was estimated by the method of Trinder [13]. Hemoglobin (Hb) was estimated by the method of Drabkin and Austin [14]. Glycosylated hemoglobin (HbA1c) was gauged by the method of Sudhakar and Pattabiraman [15] respectively. Plasma insulin was measured by the method of Burgi *et al.* [16].

## 2.6 Oral glucose tolerance test (OGTT)

For oral glucose tolerance test, animals have fasted overnight and blood glucose was estimated using On-Call Plus blood glucose test strips at various time periods (30, 60 and 120 min) after giving the oral glucose load (2.0 g/kg b.w). Blood glucose value before giving glucose load is considered as 0-minute value. Results are expressed as mg/dL.

## 2.7 Insulin sensitivity indices

Insulin sensitivity was assessed by computing homeostatic model assessment (HOMA) by the method of Matthews *et al.* [17].

## 2.8 Liver function markers

Liver function markers including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphate (ALP) were measured using biochemical-assay kits procured from Spinreact, Spain using Semi-Automated Biochemistry Analyser System Frankel and Kind and King's method [18,19].

## 2.9 Determination of carbohydrate metabolic enzymes and glycogen content

Hepatic glucokinase activity was assayed by the method of Brandstrup *et al.* [20]. Glucose-6-phosphate dehydrogenase activity was assayed by the method of Bergmeyer [21]. The activity of glucose-6-phosphatase was assayed by the method of Koide and Oda [22]. Fructose-1,6-bisphosphatase activity was measured by the method of Gancedo and Gancedo [23]. Phosphoenolpyruvate carboxykinase (PEPCK) activity was measured by the method of Bentle and lardy [24]. Glycogen content in liver and their primary metabolic enzymes was estimated by the method of Morales *et al.* [25], Golden *et al.* [26] and Shull *et al.* [27].

## 2.10 Histopathology


Liver histopathological hematoxylin and eosin staining (H&E) study were done by the method of hine [28]. For histological examination, a portion of the liver was fixed in 10% neutral buffered formalin embedded in paraffin, sectioned and stained with H&E dye. Then semi-thin sections (0.5–1 microns) were prepared by using LKB ultramicrotome. Selected sections were stained with toluidine blue, examined with a light microscope and photographed.

## 2.11 Statistical analysis

The data obtained were analyzed by one-way analysis of variance (ANOVA) and Duncan's multiple comparison tests to assess the significance of individual asymmetries between the control and treatment groups using a computer-based software SPSS version 17 (SPSS, Chicago, IL, USA). The significance was considered at the level of  $p < 0.05$ .

## 3. Results

Feed-behavior alteration induced by the diet inclusive of fat-rich animal-based (bovine) substances was characterized by comparing temporal food intake rate and initial body weight gain in HFD-group with normal-group (Table 1). Moreover, the effective therapeutic dose (TD) of test-drug (Cuminaldehyde) was formulated after evaluating FER, HOMA, HbA1c and Hb readings along with feed-rate and mass-gain in test-groups. Feeding the diet rich in animal-fat indeed increased food intake and body weight, whereas, administering plant-based fat-soluble drug dose-dependently decreased food consumption, weight gain, HOMA, HbA1c and improved FER as well as Hb levels significantly in test-groups as presented in Table 1. This information was correlated with the graphical distribution obtained with the oral glucose tolerance test depicted in Fig. 1. From the data, the effective TD was found to be 10 mg/kg body weight due to its shared insignificant criterion with control group.



**Fig. 1. Effect of cuminaldehyde on oral glucose tolerance test (OGTT).** Values were means  $\pm$  SD for six samples from six mice ( $n = 6$ ) in each group. Values not sharing a common superscript differ significantly at  $p < 0.05$  (DMRT).

The feature of effective TD (10 mg/kg b.w) was once again validated to eliminate chaos in the empirical results obtained with experimental animal models. The obtained plasma glucose values and insulin levels of test-group supplemented with 10 mg/kg b.w of CA was closest to the range of control group (Table 2). Hence, the above-mentioned statement not only informs about hyperglycemic and diet-associated diabetogenic effects of preferring fatty animal-based meal, it also confirms the hypoglycemic and insulin-resistance reverting effects of dose-effective

**Table 1. Effect of cuminaldehyde on the food intake, initial and final body weight, FER, HOMA, HbA1c, and Hemoglobin of normal and experimental mice.**

Groups	Food intake (g/mice/day)	Initial Body weight (g)	Final Body weight (g)	FER*	HOMA	HbA1c (mg/g of Hb)	Hb (g/dL)
Normal	3.22 ± 0.24 <sup>a</sup>	22.01 ± 1.67 <sup>a</sup>	33.11 ± 2.53 <sup>a</sup>	0.290 ± 0.04 <sup>a</sup>	4.20 ± 0.32 <sup>a</sup>	0.581 ± 0.04 <sup>a</sup>	10.52 ± 0.80 <sup>a</sup>
Normal + cuminaldehyde 10 mg/kg b.w	3.22 ± 0.24 <sup>a</sup>	22.11 ± 1.69 <sup>a</sup>	34.25 ± 2.60 <sup>a</sup>	0.265 ± 0.05 <sup>a</sup>	3.80 ± 0.29 <sup>a</sup>	0.580 ± 0.04 <sup>a</sup>	10.48 ± 0.79 <sup>a</sup>
HFD	3.36 ± 0.25 <sup>b</sup>	23.10 ± 1.76 <sup>a</sup>	46.08 ± 3.52 <sup>b</sup>	0.146 ± 0.02 <sup>b</sup>	21.00 ± 1.60 <sup>b</sup>	1.82 ± 0.13 <sup>b</sup>	6.92 ± 0.52 <sup>b</sup>
HFD + cuminaldehyde 2.5 mg/kg b.w	3.31 ± 0.25 <sup>b</sup>	22.06 ± 1.68 <sup>a</sup>	42.17 ± 3.21 <sup>b</sup>	0.164 ± 0.05 <sup>c</sup>	14.81 ± 1.13 <sup>c</sup>	1.54 ± 0.11 <sup>c</sup>	7.40 ± 0.56 <sup>b</sup>
HFD + cuminaldehyde 5 mg/kg b.w	3.30 ± 0.25 <sup>b</sup>	23.10 ± 1.76 <sup>a</sup>	40.20 ± 3.06 <sup>c</sup>	0.192 ± 0.01 <sup>d</sup>	10.81 ± 0.83 <sup>d</sup>	1.10 ± 0.08 <sup>d</sup>	8.90 ± 0.67 <sup>c</sup>
HFD + cuminaldehyde 10 mg/kg b.w	3.28 ± 0.25 <sup>a</sup>	23.50 ± 1.78 <sup>a</sup>	38.54 ± 2.95 <sup>d</sup>	0.218 ± 0.03 <sup>e</sup>	5.70 ± 0.43 <sup>e</sup>	0.68 ± 0.04 <sup>e</sup>	9.40 ± 0.72 <sup>d</sup>

Values are mean ± S.D. (n = 6). Means in the same row not sharing a common letter are significantly different at  $p < 0.05$  (DMRT). FER: food efficiency ratio = food intake/body weight gain. HOMA of insulin resistance (HOMA-IR) was calculated by using the formula (insulin ( $\mu$ U/mL)  $\times$  plasma glucose (mg/dL)/2430.

**Table 2. Effect of cuminaldehyde supplementation on glucose, insulin in normal and experimental mice.**

Groups	Glucose (mg/dL)	Insulin ( $\mu$ U/mL)
Normal	89.16 ± 6.79 <sup>a</sup>	19.22 ± 1.46 <sup>a</sup>
Normal + cuminaldehyde (10 mg/kg b.w)	88.49 ± 6.77 <sup>a</sup>	17.36 ± 1.33 <sup>a</sup>
HFD	216.24 ± 16.47 <sup>b</sup>	39.41 ± 3.00 <sup>b</sup>
HFD + cuminaldehyde 2.5 g/kg b.w	190.30 ± 14.57 <sup>c</sup>	31.42 ± 2.40 <sup>c</sup>
HFD + cuminaldehyde 5 mg/kg b.w	151.23 ± 11.52 <sup>d</sup>	29.07 ± 2.23 <sup>d</sup>
HFD + cuminaldehyde (10 mg/kg b.w)	104.42 ± 7.95 <sup>e</sup>	22.15 ± 1.69 <sup>e</sup>

Values were means ± SD for six samples from six mice (n = 6) in each group. Values not sharing a common superscript differ significantly at  $p < 0.05$  (DMRT).

**Table 3. Effect of cuminaldehyde on carbohydrate metabolic enzymes in normal and experimental mice.**

Groups	Glucokinase ( $\mu$ moles of glucose phosphorylated/h/mg protein)	Glucose 6 phosphate dehydrogenase (nmol of NADPH formed/min/mg protein)
Normal	0.40 ± 0.03 <sup>a</sup>	4.45 ± 0.34 <sup>a</sup>
Normal + cuminaldehyde (10 mg/kg b.w)	0.39 ± 0.03 <sup>a</sup>	4.29 ± 0.32 <sup>a</sup>
HFD	0.15 ± 0.01 <sup>b</sup>	2.49 ± 0.18 <sup>b</sup>
HFD + cuminaldehyde (10 mg/kg b.w)	0.30 ± 0.02 <sup>c</sup>	3.80 ± 0.28 <sup>c</sup>

Values were means ± SD for six samples from six mice (n = 6) in each group. Values not sharing a common superscript differ significantly at  $p < 0.05$  (DMRT).



CA input. Therefore, further reports on biochemical/histopathological analyses will be consisting of 10 mg/kg b.w of CA alone without including 2.5 and 5 counterparts in the attempt to concise the content of current treatises.

Persistence of insulin-insensitivity in HFD-group under/over-expressed glycolytic/gluconeogenic effector enzymes as represented in Table 3,4 respectively. The impact of heavy-calorie ingestion severely down-regulated chief glucose utilizing enzymes of the cytosol popularly known as glucokinase and glucose-6-phosphate dehydrogenase. The pathogenic over-expression caused by animal-fat mediated feed-behavior attenuation accumulated remarkably high amounts of Glucose 6 phosphatase ( $0.53 \pm 0.04$   $\mu$ moles of Pi liberated/min/mg protein), Fructose 1,6- biphosphatase ( $1.19 \pm 0.09$   $\mu$ moles of Pi liberated/hour/mg protein) and PEPCK ( $3.90 \pm 0.29$   $\mu$ moles of glucose phosphorylated/h/mg protein). Furthermore, normal-group had  $0.17 \pm 0.01$   $\mu$ moles of Pi liberated/hour/mg protein,  $0.50 \pm 0.03$   $\mu$ moles of Pi liberated/hour/mg protein and  $2.46 \pm 0.18$   $\mu$ moles of glucose phosphorylated/h/mg protein respectively of Glucose 6 phosphatase, Fructose 1,6- biphosphatase and PEPCK. Inclusion of CA in control-group did not alter the test-control results much; however, deprived/elevated levels of above-mentioned enzymes existed with affected-group was effectively corrected with considerable CA oral-dosage. Nevertheless, the balancing act of plant-based fat-soluble mono-terpenoid cumin-aldehyde in fine-tuning irreversible mono-saccharide utilizing steps was very profound.

The upsurge of aspartate and alanine transaminase activities along with phosphomonoester dephosphorylation via upregulation of AST, ALT and ALP enzymatic machineries respectively in the HFD-group (Fig. 2) suggested the presence of the disordered liver state. Uptake of excess non-sugar biomolecules in terms of amino/fatty acids to compensate the energy/carbon-skeleton needs of compromised glycolytic/tri-carboxylic acid cycles were diagnosed accordingly during the diabetic-onset. This error-prone diversion/dissipation (alternative) pathway simultaneously took-place with disrupting hepatocytes of mice undergoing diabetic-distress as illustrated in Fig. 3. Although, addition of tiny CA dose (10 mg/kg b.w) as an oral-supplement significantly ( $p < 0.05$ ) curtailed the upsurge/upregulation (pathological exaggeration) of transaminases cum phosphatases and recycled/replenished (physiological re-expression) major hepatocytic cycles/conditions respectively. In addition, the dietary CA potentially stepped-up the distribution of glycogen synthase by diminishing the domination of glycogen phosphorylase aided the test-group to restore their respective glycogen reserves (Table 5). Therefore, the data was very consistent and evident to support the anti-diabetogenic and anti-transaminitis characteristics of the administered dose-effective plant-based fat-soluble drug.

## 4. Discussion

Out of innate and acquired metabolic disorders (type I and II diabetic mellites respectively), the later condition (T2D) occurs presumably due to improper dietary-selection, which primarily affects micro/macro-vasculature (neuro endocrine and cardiovascular-networks) of humans/mice hosts [29]. Compromised hypo-glycemic hormonal-signaling could cause insulin-receptor (IR) dysfunction in cellular-surface/membrane, as a consequence, it omits vital sugar-uptake in a viable/respiring-cell. Committed dimeric-autophosphorylation of IR cum irreversible catabolic-dehydrogenation of glycosyl-subunits via kinase/oxidoreductase pathway(s) are important for the uptake and utilization of glucose. Thermo-homeostatic multi-cellular hydro-chemical medium has high fidelity in facilitating systemic-connectivity and transcellular-communication bio-responses for promoting cum progressing of cellular-operations [30]. Pancreatic-cells are capable of sensing external cum internal status of the body with its dual exocrine-endocrine receptocytes via gastrointestinal tract and cardio-vascular network respectively [31]. Caloric-density (light vs heavy) seems to be the major determining factor for metabolic-threshold (free/fatty ergogenic kinetics) maintenance in the chosen mammalian animal-model of the current study. Catabolic-perturbation thus took-place because of the disturbance projected/propelled by highly-saturated fatty-components transiting in GI tract/CV network could be the most crucial contributor for pathogenic-transformation of proximate-organs participating in the circulatory, secretory and excretory processes. Altered feed-behavior along with adulterated energy-exchange patterns in the affected individuals of diet-associated diabetic-distress implies negative-effects of consuming animal-based meal which comprises larger-amounts of long-chain saturated fatty-acids capable of proliferating hydro-peroxidation.

Glucose is the primary fuel/nutrient metabolite for many life domains ranging from prokaryote to eukaryote [32]. The six-carbon biomolecule (hexose pyran) is vastly abundant in this planet and so many heterotrophic organisms including mammals mainly depend on this monosaccharide moiety for caloric cum carbonic needs. The cycles that utilize glucose (metabolic-fate) is said to be constitutive because of the overwhelmed demand in cellular respiratory compartments for assuring metabolic-flow/continuum. In plants, the photo-synthetic pathway fixes CO<sub>2</sub> to produce this particular sugar via ribulose-bis-phosphate carboxylase/oxygenase (rubisco), surplus sugars are converted to starch (storage polysaccharide) for later utilization. In animals (especially with endocrine system), excess glucose is spontaneously converted into highly branched glycogen and stored in the liver/muscle tissues under finely regulated biochemical signaling cascade. However, during metabolic stress conditions, the bio-conversion and storage of glucose seem to be partially ceased or improperly monitored. Diet-

**Table 4. Effect of cuminaldehyde supplementation on gluconeogenic enzymes in normal and experimental mice.**


Groups	Glucose 6 phosphatase ( $\mu$ moles of Pi liberated/min/mg protein)	Fructose 1,6- bisphosphatase ( $\mu$ moles of Pi liberated/hour/mg protein)	PEPCK ( $\mu$ moles of glucose phosphorylated/h/mg protein)
Normal	$0.17 \pm 0.01^a$	$0.50 \pm 0.03^a$	$2.46 \pm 0.18^a$
Normal + cuminaldehyde (10 mg/kg b.w)	$0.18 \pm 0.01^a$	$0.49 \pm 0.03^a$	$2.43 \pm 0.18^a$
HFD	$0.53 \pm 0.04^b$	$1.19 \pm 0.09^b$	$3.90 \pm 0.29^b$
HFD + cuminaldehyde (10 mg/kg b.w)	$0.25 \pm 0.01^c$	$0.65 \pm 0.04^c$	$2.84 \pm 0.21^c$

Values were means  $\pm$  SD for six samples from six mice (n = 6) in each group. Values not sharing a common superscript differ significantly at  $p < 0.05$  (DMRT).

**Table 5. Effect of cuminaldehyde supplementation on liver glycogen, glycogen synthase, and glycogen phosphorylase in normal and experimental mice.**

Groups	Glycogen (mg/100g tissue)	Glycogen synthase ( $\mu$ moles of UDP formed/h/mg protein)	Glycogen phosphorylase ( $\mu$ moles of Pi liberated/h/mg protein)
Normal	$66.01 \pm 5.02^a$	$640.10 \pm 48.74^a$	$580.29 \pm 44.4^a$
Normal + cuminaldehyde (10 mg/kg b.w)	$68.03 \pm 5.20^a$	$635.10 \pm 48.36^a$	$576.09 \pm 43.8^a$
HFD	$30.00 \pm 2.28^b$	$450.22 \pm 34.46^b$	$630.10 \pm 47.9^b$
HFD + cuminaldehyde (10 mg/kg b.w)	$50.02 \pm 3.82^c$	$560.09 \pm 42.64^c$	$600.30 \pm 45.9^c$

Values were means  $\pm$  SD for six samples from six mice (n = 6) in each group. Values not sharing a common superscript differ significantly at  $p < 0.05$  (DMRT).




**Fig. 2. Effect of cuminaldehyde on liver function markers (ALT, AST, and ALP) in normal and experimental mice.** Values were means  $\pm$  SD for six samples from six mice (n = 6) in each group. Values not sharing a common superscript differ significantly at  $p < 0.05$  (DMRT).

associated diabetic distress (T2D) or non-insulin dependent diabetes mellitus (NIDDM) is popularly known to cause the above-mentioned prolonging-pathogenic response in humans with logarithmic global-prevalence [33]. Ingestion of saturated fats (fatty/heavy calorie-meal) was identified and inferred as a causative factor for T2D/NIDDM among humans and genetically manipulated lab mice.

The animals fed (HFD-group) with rich bovine-fat diet indeed developed signs and symptoms of NIDDM, which includes temporally increased body weight, food intake (polyphagia) and post-prandial blood glucose/insulin

levels than the control group. It significantly brought down the levels of plasma hemoglobin (Hb) simultaneously by increasing its glycated version (HbA1c) and homeostatic assessment (HOMA) value used to forecast insulin-resistance [34]. This confirms the development of diabetic-distress in-terms of hyperglycemia and hyperinsulinemia among affected animals grown on periodic HFD pattern. In the physiological condition, glucokinase and glucose 6 phosphate dehydrogenase (G6P-DHase) utilizes glucose by means of spontaneous oxidative-phosphorylation steps [35]. However, the pathological (animal-fat fed)



**Fig. 3. Photomicrographs of hematoxylin and eosin stained section of mice liver (100× standard light magnification).** Depicts the photomicrographs of H & E staining of liver tissue of control and experimental mice. Normal mice liver showing normal nucleus and hepatocytes (A). Normal mice treated with CA (10 mg/kg) showed the presence of the normal nucleus, sinusoids and central vein (B). Diabetic control mice showed the disappearance of nuclei, degeneration of sinusoids & central vein and portal inflammation (C). CA treatment (10 mg/kg b.w) reversed these changes to near normal in diabetic mice (D).

mice group expressed abnormally low levels of constitutive sugar utilizing enzymes. Additionally, the over-expression of gluconeogenic enzymatic machineries such as glucose 6 phosphatase, fructose 1,6- biphosphatase and phosphoenolpyruvate carboxykinase supports prevailing pathogenicity in the HFD-population.

Oral-supplementation of plant-based fat-soluble monocyclic-terpenoid cuminaldehyde (CA) provided to HFD-subjects exhibited anti-glycemic/insulinemic activity and enhanced food efficiency ratio (FER) closer to the control-counterpart. It stepped-up the bio-activity of sugar-utilizing glucokinase/glucose-phosphate-dehydrogenase enzymes which involves in producing vital intracellular redox-potentials such as NADH/NADPH respectively via glycolysis/HMP-shunt. Surprisingly [36], the selected-

dose TD C (10 mg/kg b.w) of supplementary-drug (CA) suppressed the upsurge of above-mentioned gluconeogenic effector-enzymes including transaminases (ALT/AST) and phosphatases (ALP family) in the blood-serum. The latter statement provides the evidence that the administered-drug in test-group (HFD-diet + CA) is profoundly capable of counteracting the developing demand to consume non-sugar components for partially fulfilling current caloric cum carbonic pre-requirements. Nevertheless, the conversion of surplus monomeric glycosyl-monosaccharides into storable multimeric pyranosyl-polysaccharides was favored by the implemented dose-effective drug devoid of any observable metabolic toxicity. The previous study preferred 5 mg/kg b.w of CA as effective therapeutic-dose for treating streptozotocin-induced diabetic-distress [37].



In the current study with HFD design, we recommend a slightly higher concentration of CA i.e., 10 mg/kg b.w because of its insignificance with normal-group and efficacy with abnormal-group.

## 5. Conclusions

Pancreatic-organ plays a crucial role in governing basal metabolic-rate/fate and maintaining homeostatic-threshold by monitoring gastrointestinal-tract and cardiovascular-network via collective hydrolytic enzymes and selective signaling hormones represented as exocrine detectors and endocrine effectors respectively. The inter-connecting cum trans-communicating signals for conjugating and mediating peripheral tissues to promote uptake, utilization or storage of fuel (glucosyl-subunits) according to the energy consumptive/conservative demand by provoking commitment and completent duo. This dual-purpose gland located near duodenum seems more sensitive to the caloric-density of ingested-material, highly saturated bovine fat imposed deleterious side-effects in the body of mice with insulin-insensitive diabetic-onset. The latter condition lowered food-efficiency ratio and hemoglobin levels simultaneously by enhancing post-prandial blood-glucose, insulin, and glycated-hemoglobin partial-pressures. The load exerted from fatty-diet created deteriorative stress in committed oxidation/phosphorylation reactions of constitutive energy assimilative/transformative processes of chemo-respiration. The availability of surplus transaminases implies intensive leakage of high-energetic (caloric) keto-acids and extensive breakage of aspartyl-alanyl amino-acyl (carbonic) derivatives. The demand shifted towards gluconeogenic cycle rather than the glycogenic pathway suggests the chaos in respiratory-redox balance due to improper feed-behavior pattern of pathogenic subjects. However, the induced redox-imbalance can be counteracted with the introduction of fat-soluble redox-carriers containing phenyl-nucleus and carbonyl-terminal for complementing electron-shuttling and proton-pumping across membranal-matrix/space interface respectively. The prophylaxis promoted via exogenous photo-respiratory redox-potentials of monocyclic-terpenoid cuminaldehyde (CA) most probably participated in the replenishment of endogenous redox-adapters and restored glucose-catabolizing enzymes. Therefore, pathological-complications such as hyperglycemia, hyperinsulinemia, and transaminitis can be profoundly prevented by preferring plant-based semi-oxidized fat-soluble redox-couplers such as CA in required amounts (10 mg/kg b.w) orally to establish effective therapeutic dose-action.

## Abbreviations

CA, Cuminaldehyde; FER, food efficiency ratio; Hb, hemoglobin; HbA<sub>1c</sub>, glycosylated hemoglobin; HFD, high-fat diet; HOMA - IR, Homeostatic model assessment - insulin resistance; OGTT, Oral Glucose Tolerance Test;

PEPCK, Phosphoenolpyruvate carboxykinase; TD, Therapeutic dose.

## Author contributions

KD and PL designed the study, supervised the data collection, analyzed the data, KD interpreted the data and prepare the manuscript for publication, PE, PR, SJ, SB and TDSB supervised the data collection, analyzed the data and reviewed the draft of the manuscript. All authors have read and approved the manuscript.

## Ethics approval and consent to participate

Ethical approval was obtained from the Ethics Committee of the Ethics Committee of the First Affiliated Rajah Muthiah Medical College and Hospital, Annamalai University, Annamalai Nagar, Animals were maintained as per the National Guidelines and Protocols approved by the Institutional Animal Ethics committee (Reg. No. 160/ 1999/CPC-SEA, Proposal number: 1166 in 2017).

## Acknowledgment

Not applicable.

## Funding

This research received no external funding.

## Conflict of interest

The authors declare no conflict of interest.

## References

- [1] American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2012; 35: S64–S71.
- [2] Aynalem SB, Zeleke AJ. Prevalence of diabetes mellitus and its risk factors among individuals aged 15 years and above in mizan-aman town, southwest ethiopia, 2016: a cross sectional study. *International Journal of Endocrinology*. 2018; 2018: 1–7.
- [3] Gothai S, Ganesan P, Park SY, Fakurazi S, Choi DK, Arulselvan P. Natural phyto-bioactive compounds for the treatment of type 2 diabetes: inflammation allergy drug targets. *Nutrients*. 2016; 8: E461
- [4] Choudhury H, Pandey M, Hua CK, Mun CS, Jing JK, Kong L, *et al*. An update on natural compounds in the remedy of diabetes mellitus: a systematic review. *Journal of Traditional and Complementary Medicine*. 2017; 8: 361–376.
- [5] Patel D, Prasad S, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. *Asian Pacific Journal of Tropical Biomedicine*. 2012; 2: 320–330.
- [6] Singh RP, H.V. G, K M. *Cuminum cyminum* - a popular spice: an updated review. *Pharmacognosy Journal*. 2017; 9: 292–301.
- [7] Lee HS. Cuminaldehyde: aldose reductase and alpha-glucosidase inhibitor derived from *cuminum cyminum* L. Seeds. *Journal of Agricultural and Food Chemistry*. 2005; 53: 2446–2450.
- [8] Chen T, Tsai K, Yang S, Wong H, Liu Y, Cherg J, *et al*. Discovery of a novel anti-cancer agent targeting both topoisomerase I & II as well as telomerase activities in human lung adenocarcinoma a549 cells *in vitro* and *in vivo*: *Cinnamomum verum* com-



- ponent cuminaldehyde. *Current Cancer Drug Targets*. 2016; 16: 796–806.
- [9] Wei J, Zhang X, Bi Y, Miao R, Zhang Z, Su H. Anti-Inflammatory effects of cumin essential oil by blocking JNK, ERK, and NF- $\kappa$ B signaling pathways in LPS-stimulated RAW 264.7 Cells. *Evidence-Based Complementary and Alternative Medicine*. 2015; 2015: 474509.
  - [10] Zheljaskov VD, Gawde A, Cantrell CL, Astatkie T, Schlegel V. Distillation time as tool for improved antimalarial activity and differential oil composition of cumin seed oil. *PLoS ONE*. 2015; 10: e0144120.
  - [11] Kedia A, Prakash B, Mishra PK, Dubey NK. Antifungal and anti-aflatoxicogenic properties of *Cuminum cyminum* (L.) seed essential oil and its efficacy as a preservative in stored commodities. *International Journal of Food Microbiology*. 2014; 168–169: 1–7.
  - [12] Muthulakshmi S, Saravanan R. Protective effects of azelaic acid against high-fat diet-induced oxidative stress in liver, kidney and heart of C57BL/6J mice. *Molecular and Cellular Biochemistry*. 2013; 377: 23–33.
  - [13] Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. *Journal of Clinical Pathology*. 1969; 22: 158–161.
  - [14] Drabkin DL, Austin JM. Spectrophotometric constants for common haemoglobin derivatives in human, dog and rabbit blood. *Journal of Biological Chemistry*. 1932; 98: 719–733.
  - [15] Sudhakar NS, Pattabiraman TN. A new colorimetric method for the estimation of glycosylated haemoglobin. *Clinica Chimica Acta*. 1981; 109: 267–274.
  - [16] Bürgi W, Briner M, Franken N, Kessler AC. One-step sandwich enzyme immunoassay for insulin using monoclonal antibodies. *Clinical Biochemistry*. 1988; 21: 311–314.
  - [17] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985; 28: 412–419.
  - [18] Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. *American Journal of Clinical Pathology*. 1957; 28: 56–63.
  - [19] Kind PN, King EJ. Estimation of plasma phosphate by determination of hydrolyzed phenol with aminopyrines. *Journal of Clinical Pathology*. 1954; 7: 322–323.
  - [20] Brandstrup N, Kirk JE, Bruni C. The hexokinase and phosphoglucosomerase activities of aortic and pulmonary artery tissue in individuals of various ages. *The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences*. 1957; 12: 166–171.
  - [21] Bergmeyer HU. Glucose 6-phosphate dehydrogenase. In: Bergmeyer, H.U. (Ed). *Methods of Enzymatic Analysis*, Verlag Chemie (pp. 222–223). Weinheim: Archiv der Pharmazie. 1984.
  - [22] Hikaru K, Toshitsugu O. Pathological occurrence of glucose 6-phosphatase in serum in liver diseases. *Clinica Chimica Acta*. 1959; 4: 554–561.
  - [23] Gancedo JM, Gancedo C. Fructose-1, 6-diphosphatase, phosphofructokinase and glucose-6-phosphate dehydrogenase from fermenting and non-fermenting yeasts. *Archives of Microbiology*. 1971; 76: 132–138.
  - [24] Bentle LA, Lardy HA. Interaction of anions and divalent metal ions with phosphoenolpyruvate carboxykinase. *The Journal of Biological Chemistry*. 1976; 251: 2916–2921.
  - [25] Morales MA, Jobaggy AJ, Terenzi HF. Mutations affecting accumulation of glycogen. *Fungal Genetics and Biology*. 1975; 20: 22.
  - [26] Golden S, Wals PA, Katz J. An improved procedure for the assay of glycogen synthase and phosphorylase in rat liver homogenates. *Analytical Biochemistry*. 1977; 77: 436–445.
  - [27] Shull KH, Ashmore J, Mayer J. Hexokinase, glucose-6-phosphatase and phosphorylase levels in hereditarily obese-hyperglycemic mice. *Archives of Biochemistry and Biophysics*. 1956; 62: 210–216.
  - [28] Hine IF. Block staining of mammalian tissues with hematoxylin and eosin. *Stain Technology*. 1981; 56: 119–123.
  - [29] Zhang M, Lv X, Li J, Xu Z, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. *Experimental Diabetes Research*. 2008; 2008: 704045.
  - [30] Lee SH, Zabolotny JM, Huang H, Lee, Kim YB. Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. *Molecular Metabolism*. 2016; 5: 589–601.
  - [31] Kelleher SL, McCormick NH, Velasquez V, Lopez V. Zinc in specialized secretory tissues: roles in the pancreas, prostate, and mammary gland. *Advances in Nutrition*. 2011; 2: 101–111.
  - [32] Lane N. Energetics and genetics across the prokaryote-eukaryote divide. *Biology Direct*. 2011; 6: 35.
  - [33] Sami W, Ansari T, Butt NS, Hamid MRA. Effect of diet on type 2 diabetes mellitus: A review. *International Journal of Health Sciences (Qassim)*. 2017; 11: 65–71.
  - [34] Williams LM, Campbell FM, Drew JE, Koch C, Hoggard N, Rees WD, Kamolrat T, Thi H Ngo, Steffensen IL, Gray SR, Tups A. The development of diet-induced obesity and glucose intolerance in C57BL/6 mice on a high-fat diet consists of distinct phases. *PLoS ONE*. 2014; 9: e106159.
  - [35] Lu H, Bogdanovic E, Yu Z, Cho C, Liu L, Ho K, Guo J, Yeung LSN, Lehmann R, Hundal HS, Giacca A, Fantus IG. Combined Hyperglycemia- and Hyperinsulinemia-Induced Insulin Resistance in Adipocytes Is Associated With Dual Signaling Defects Mediated by PKC- $\zeta$ . *Endocrinology*. 2018; 159: 1658–1677.
  - [36] Kim YM, Heinzel N, JO Giese, Koeber J, Melzer M, Rutten T, Von Wiren N, Sonnewald U, Hajirezaei MR. A dual role of tobacco hexokinase 1 in primary metabolism and sugar sensing. *Plant, Cell & Environment*. 2013; 36: 1311–1327.
  - [37] Patil SB, Takalikar SS, Joglekar MM, Haldavnekar VS, Arvindkar AU. Insulinotropic and  $\beta$ -cell protective action of cuminaldehyde, cuminol and an inhibitor isolated from *Cuminum cyminum* in streptozotocin-induced diabetic rats. *British Journal of Nutrition*. 2013; 110: 1434–1443.